Gsk (GSK) Interest Expenses (2009 - 2026)

Gsk (GSK) has 18 years of Interest Expenses data on file, last reported at -$468.6 million in Q3 2026.

• For the quarter ending Q3 2026, Interest Expenses changed N/A year-over-year to -$468.6 million; the trailing twelve-month figure through Sep 2026 stood at -$1.9 billion (changed N/A YoY), and the FY2025 full-year result was -$932.4 million, down 9.04% from the prior year.
• Interest Expenses was -$468.6 million for Q3 2026 at Gsk, down from -$244.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of -$202.7 million in Q3 2024 to a low of -$1.0 billion in Q4 2022.
• A 5-year average of -$396.2 million and a median of -$244.2 million in 2026 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses sank 97.63% in 2022 and increased 14.66% in 2024, its largest moves.
• Gsk's Interest Expenses stood at -$1.0 billion in 2022, then gained by 4.66% to -$983.0 million in 2023, then advanced by 12.65% to -$858.7 million in 2024, then slipped by 8.59% to -$932.4 million in 2025, then soared by 49.75% to -$468.6 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were -$468.6 million in Q3 2026, -$244.2 million in Q2 2026, and -$225.1 million in Q1 2026.